Articles
By Phoebe Starr
Enzalutamide (Xtandi) and apalutamide (Erleada) had strong showings in 2 separate, randomized phase 3 clinical trials demonstrating that these drugs delay disease progression when added to background androgen-deprivation therapy (ADT) in patients with metastatic, hormone-sensitive prostate cancer. Read More ›
By Phoebe Starr
Maintenance therapy with the targeted drug olaparib (Lynparza) after first-line platinum-based chemotherapy prolonged progression-free survival (PFS) in patients with metastatic pancreatic cancer and a germline BRCA mutation, according to results of the phase 3 POLO clinical trial presented at the plenary session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Read More ›
This section provides a brief overview of new cancer drugs or new indications approved by the FDA between June 10 and July 3, 2019. Read More ›
Skin cancer is the most frequently diagnosed malignancy in the United States. Although invasive melanoma comprises approximately 1% of skin cancers, it is the cause of a vast majority of skin cancer–related deaths. The following provides helpful information related to this malignancy. Read More ›
Genetic alterations in molecular pathways are involved in tumor development, survival, and progression. Read More ›
By Chase Doyle
Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses a patient’s own genetically modified T-cells to fight cancer. Read More ›
Lung cancer is the second most frequently diagnosed malignancy in both men and women (following prostate and breast cancer, respectively), and the leading cause of cancer deaths overall. Non–small-cell lung cancer (NSCLC) is the most common type, with the more aggressive small-cell lung cancer (SCLC) making up approximately 10% to 15% of cases. Read More ›
On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval to the novel antibody-drug conjugate polatuzumab vedotin-piiq (Polivy; Genentech) in combination with bendamustine plus rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least 2 previous therapies. This is the first chemoimmunotherapy regimen approved for use in patients with DLBCL who are ineligible for hematopoietic stem-cell transplantation. Read More ›
The Lynx Group is pleased to bring you the Fourth Annual Oncology Guide to New FDA Approvals. The goal of this Guide is to offer oncologists, pharmacists, oncology nurses, and other healthcare stakeholders a comprehensive overview of new drugs approved by the US Food and Drug administration (FDA) in 2018 for the treatment of different types of cancer, including hematologic and oncologic malignancies. This practical tool offers a quick, evidence-based resource for hematology/oncology professionals to guide their medication-related decision-making and help ensure the administration of recent medicines for appropriate patients. Read More ›
- Introduction
- Oncology Overview
- Breast Cancer New Indications
- Genitourinary Cancers New Indications
- Gynecologic Cancers New Indications
- Hematologic Malignancies New Indications
- Lung Cancer New Indications
- Other Tumor Types New Indications